Orphazyme A/S
Company announcement                                                                                                                  
No. 05/2019                                                                                                                                        
Company Registration No. 32266355                                                                                                                                                                                     

 

Copenhagen, Denmark, March 1, 2019 – Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme in connection with the vesting of Matching Shares:

1 Details of the Reporting Person / Closely Associated Person
a) Name
Anders Hinsby
2 Reason for the notification
a) Position/status
Chief Executive Officer
b) Initial notification/Amendment
Initial notification
3 Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name
Orphazyme A/S
b) LEI code
54930025OZD2GGSQ7L42
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code
Shares
ISIN DK0060910917
b) Nature of the transaction
Vesting of Matching Shares
c) Price(s) and volume(s)

Price (s)	Volume(s)
DKK 1.00	5,000

d) Aggregated information

 

• Aggregated volume
• Price

 

e) Date of the transaction
March 4, 2019
f) Place of the transaction
Outside a trading venue

1 Details of the Reporting Person / Closely Associated Person
a) Name
Anders Vadsholt
2 Reason for the notification
a) Position/status
Chief Financial Officer
b) Initial notification/Amendment
Initial notification
3 Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name
Orphazyme A/S
b) LEI code
54930025OZD2GGSQ7L42
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code
Shares
ISIN DK0060910917
b) Nature of the transaction
Vesting of Matching Shares
c) Price(s) and volume(s)

Price (s)	Volume(s)
DKK 1.00	4,000

d) Aggregated information

 

• Aggregated volume
• Price

 

e) Date of the transaction
March 4, 2019
f) Place of the transaction
Outside a trading venue

1 Details of the Reporting Person / Closely Associated Person
a) Name
Thomas Kirkegaard Jensen
2 Reason for the notification
a) Position/status
Chief Scientific Officer
b) Initial notification/Amendment
Initial notification
3 Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name
Orphazyme A/S
b) LEI code
54930025OZD2GGSQ7L42
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code
Shares
ISIN DK0060910917
b) Nature of the transaction
Vesting of Matching Shares
c) Price(s) and volume(s)

Price (s)	Volume(s)
DKK 1.00	4,000

d) Aggregated information

 

• Aggregated volume
• Price

 

e) Date of the transaction
March 4, 2019
f) Place of the transaction
Outside a trading venue

1 Details of the Reporting Person / Closely Associated Person
a) Name
Thomas Blaettler
2 Reason for the notification
a) Position/status
Chief Medical Officer
b) Initial notification/Amendment
Initial notification
3 Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name
Orphazyme A/S
b) LEI code
54930025OZD2GGSQ7L42
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code
Shares
ISIN DK0060910917
b) Nature of the transaction
Vesting of Matching Shares
c) Price(s) and volume(s)

Price (s)	Volume(s)
DKK 1.00	1,875

d) Aggregated information

 

• Aggregated volume
• Price

 

e) Date of the transaction
March 4, 2019
f) Place of the transaction
Outside a trading venue

1 Details of the Reporting Person / Closely Associated Person
a) Name
Paul Merrigan
2 Reason for the notification
a) Position/status
Chief Commercial Officer
b) Initial notification/Amendment
Initial notification
3 Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name
Orphazyme A/S
b) LEI code
54930025OZD2GGSQ7L42
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code
Shares
ISIN DK0060910917
b) Nature of the transaction
Vesting of Matching Shares
c) Price(s) and volume(s)

Price (s)	Volume(s)
DKK 1.00	4,300

d) Aggregated information

 

• Aggregated volume
• Price

 

e) Date of the transaction
March 4, 2019
f) Place of the transaction
Outside a trading venue

 

For additional information, please contact

Orphazyme A/S
Anders Vadsholt, CFO                         +45 28 98 90 55

 

About Orphazyme A/S 
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins and lysosomal dysfunction. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com. 

Forward-looking statement
This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Attachment

Reporting of transactions in Orphazymes shares

by Michael Hove